Patients' Preference for Subcutaneous or Vaginal Progesterone as Luteal Support in IVF/ICSI Cycles
Status:
Terminated
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This randomized, controlled, prospective, crossover, open-label, two-treatments, two-period
trial aimed to evaluate the preference expressed by the patient concerning the subcutaneous
administration of progesterone versus the vaginal one.
The couples, scheduled for performing 2 In Vitro Fertilization (IVF)/Intracytoplasmic Sperm
Injection (ICSI) cycles will be randomized to receive, as luteal phase supplementation,
Pleyris 25 milligram (mg) (a single subcutaneous administration per day) or Prometrium 200 mg
(3 vaginal administrations per day).